Application US20190350949

PSILOCYBIN AND/OR PSILOCIN IN COMBINATION WITH CANNABINOIDS AND/OR TERPENES
[+] Show Details

US20190350949

1.-15. (canceled) (0)

16. A method for preventing or treating a psychological disorder, comprising: (10) (1)

administrating psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene, wherein the at least one cannabinoid and/or at least one terpene is administered separately, sequentially or simultaneously to the psilocybin and/or psilocin.

17. The method of claim 16, wherein the psychological disorder is chosen from depression, psychotic disorder, schizophrenia, schizophreniform disorder (acute schizophrenic episode); schizoaffective disorder; bipolar I disorder (mania, manic disorder, manic-depressive psychosis); bipolar II disorder; major depressive disorder with psychotic feature (psychotic depression); delusional disorders (paranoia); Shared Psychotic Disorder (Shared paranoia disorder); Brief Psychotic disorder (Other and Unspecified Reactive Psychosis); Psychotic disorder not otherwise specified (Unspecified Psychosis); paranoid personality disorder; schizoid personality disorder; schizotypal personality disorder, anxiety disorder, panic disorder, panic attacks, agoraphobia, attention deficit syndrome, premenstrual dysphoric disorder (PMDD), and premenstrual syndrome (PMS). (0)

20. The method of claim 16, wherein the at least one cannabinoid is at least one, two or three chosen from the group consisting of cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). (0)

21. The method of claim 16, wherein the at least one cannabinoid is present in the form of an extract from a cannabis plant, preferably wherein the extract has all or a proportion of THC and/or THCA selectively removed. (0)

22. The method of claim 16, wherein the at least one cannabinoid is present in a composition comprising at least 2, 3, or 4 cannabinoids. (0)

23. The method of claim 16, wherein the at least one cannabinoid is present in a pure form. (0)

24. The method of claim 16, wherein the at least one cannabinoid is present in a synthetic form. (0)

25. The method of claim 16, wherein the psilocybin and/or psilocin are present in the form of an extract from a mushroom and/or truffle (sclerotium), preferably from the genus Psilocybe, Gymnopilus, Panaeolus, Copelandia, Hypholoma, Pluteus, Inocybe, Conocybe, Panaeolina, Gerronema, Agrocybe, Galerina and/or Mycena, more preferably P. azurescens, P. semilanceata, P. cyanescens, and/or P. cubensis, P. subcubensis, P. tampanensis, P. mexicana A, P. atlantis, and/or P. semilanceata. (0)

26. The method of claim 16, wherein the psilocybin and/or psilocin are present in a pure form. (0)

27. The method of claim 16, wherein the psilocybin and/or psilocin are present in a synthetic form. (0)

28. The method of claim 16, wherein psilocybin and/or psilocin in combination with the at least one cannabinoid and/or at least one terpene are comprised in a pharmaceutical composition, preferably further comprising one or more pharmaceutically acceptable carriers, excipients or diluents. (0)

18. A method for preventing or treating a brain disorder, comprising: (1) (1)

29. A method for preventing or treating developmental disorders, delirium, dementia, amnestic disorders and other cognitive disorders, psychiatric disorders due to a somatic condition, drug-related disorders, schizophrenia and other psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, eating disorders, sleep disorders, impulse control disorders, adjustment disorders, or personality disorders, comprising: (0) (1)

30. A method for preventing or treating of ADHD, ADD, anorexia nervosa, antisocial personality disorder, autism, addiction, avoidant personality disorder, bipolar disorder, bulimia nervosa, borderline personality disorder, catatone schizophrenia, chronic motor or vocal tic disorder, conversion disorder, cyclothymia, dependent personality disorder, delier, dementia, depersonalization disorder, depression, Dhat syndrome, dissociative amnesia, dissociative fugue, dissociative identity disorder, dissociative disorder, dissociative disorder, not otherwise specified, dysthymic disorder, Da Costa's syndrome, ephobophilia, exhibitionism, generalized anxiety disorder, grandiose delusions, hypochondria, hoarding disorder, intermittent explosive disorder, jealousy, kleptomania, Klüver-Bucy syndrome, maternity psychosis, mental retardation, monomania, Münchhausen syndrome, misophony, narcissistic personality disorder, obsessive-compulsive disorder, oniomania, organic personality disorder, phobia, paranoid personality disorder, paranoid delusions, passive-aggressive personality, pathological gambling, pathological lying, personality disorder not otherwise defined (PDNOS), pervasive developmental disorder, pica, pain disorder, post encephalitic syndrome, postpartum depression, posttraumatic stress disorder, psychosis, psychotic disorder due to substance use, pyromania, querulant delusions, ruminational disorder, schizophrenia, schizoaffective disorder, schizoid personality disorder, schizotypal personality disorder, separation anxiety, social phobia, somatisation disorder, somatic delusion, somatoform disorder, syndrome of Capgras, syndrome of Cotard, syndrome of Ganser, syndrome of Gilles de la Tourette, selective mutism, theatrical personality disorder, trichotillomania, or undifferentiated somatoform disorder, comprising: (0) (1)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Application US20190350949

PSILOCYBIN AND/OR PSILOCIN IN COMBINATION WITH CANNABINOIDS AND/OR TERPENES

Patent Matrix® Search